CIK 0001603454 · Non-accelerated filer<br>Smaller reporting company
Celcuity Inc.
Sign in to watch- Ticker
- CELC
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 763-392-0767
- Business address
- 16305 36TH AVENUE N, SUITE 100, MINNEAPOLIS, MN, 55446
- Former names
- Celcuity LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −2,771 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +2,771 | 2,771 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −3,215 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +3,215 | 3,215 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −2,973 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +2,973 | 2,973 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −6,754 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +6,754 | 6,754 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −20,000 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Returned to the company · Stock Option (right to buy) | −1,877 | 0 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (right to buy) | +1,877 | 1,877 | ||
| 2022-05-17 | Laing Lance G. Chief Science Officer | Grant or award · Stock Option (Right to Buy) | +38,412 | 38,412 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −8,220 | 0 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +8,220 | 8,220 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −3,769 | 0 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +3,769 | 3,769 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −14,675 | 0 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +14,675 | 14,675 | ||
| 2022-05-17 | Sullivan Brian F. Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −50,000 | 0 |
Page 14 of 19 · 365 trades